In the present review, we describe recent advances in the development of novel soluble biomarkers (e.g., circulating immune cells, TMB, circulating tumor cells, circulating tumor DNA, soluble factor PD-L1, tumor necrosis factor, etc.)for patients with NSCLC treated with ICIs. This evidence concerns the gene CD274 and neoplasm.